{"disease":{"id":"treatment-of-covid-19-in-adults-and-pediatric-patients","name":"treatment of covid 19 in adults and pediatric patients"},"drugs":{"marketed":[{"drug_id":"nirmatrelvir-ritonavir","indication_name":"Treatment of mild to moderate COVID-19 in adults and pediatric patients (5 years of age and older) who weigh at least 40 kg.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"nirmatrelvir-ritonavir","generic_name":"nirmatrelvir-ritonavir","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 protease enzyme","drug_class":"Protease inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"part-a-atm-avi-single-dose-cohorts-1-4","indication_name":"Treatment of COVID-19 in adults and pediatric patients (12 years of age and older) who are at high risk of progression to severe COVID-19, including those who are hospitalized due to COVID-19 or who have mild to moderate COVID-19 with at least one risk factor for progression to severe COVID-19 (e.g., older age, certain chronic medical conditions)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part A: ATM-AVI Single Dose, Cohorts 1-4","generic_name":"part-a-atm-avi-single-dose-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}